SCHEMBL8810581

SCHEMBL8810581

CCOC(=O)c1cc2ccc3c(c2cc1O)OC(n1cccc1)=C(C#N)C3c1ccc(OC)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MYB P10242 8/20 0.48
▸ MEN1 O00255 5/20 0.45
▸ KMT2A Q03164 5/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ MAPT P10636 3/20 0.45
▸ CYP2C9 P11712 2/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ GAA P10253 3/20 0.44
▸ USP2 O75604 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ ALOX12 P18054 1/20 0.44
▸ POLB P06746 3/20 0.42
▸ RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8811063 0.89 MYB (0.38) MYBMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL8810573 0.88 MYB (0.61) MYBMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL8809115 0.87 ALDH1A1 (0.42) MYBMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL8811837 0.85 MYB (0.48) MYBMEN1KMT2AMAPTCYP2C9
SCHEMBL8807532 0.85 MEN1 (0.46) MEN1KMT2ASMN1; SMN2KDM4EMAPT
SCHEMBL8811862 0.80 MYB (0.74) MYBMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL8809139 0.78 MYB (0.47) MYBMEN1KMT2AMAPTCYP2C9
SCHEMBL8808823 0.78 MYB (0.50) MYBMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL8808745 0.76 MYB (0.49) MYBMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL8810798 0.74 MPO (0.51) MYBMEN1KMT2ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0618206-B1 Pharmaceutical compounds LILLY INDUSTRIES LTD (GB) 1997-09-17 — — EP disclosed
US-5576325-A TREATMENT OF IMMUNE DISEASES, RESTENOSIS, ENZYME INHIBITORS AND ANTISPASMODIC AGENTS LILLY INDUSTRIES LIMITED (GB) 1996-11-19 — — US disclosed
US-5574034-A TREATMENT OF IMMUNE DISEASES AND EXCESS CELL PROLIFERATION, ENZYME INHIBITORS ELI LILLY AND COMPANY (US) 1996-11-12 — — US disclosed
US-5571818-A FOR TREATING IMMUNE DISEASES OR A DISEASE IN WHICH EXCESS CELL PROLIFERATION OR ENZYME RELEASE OCCUR ELI LILLY AND COMPANY (US) 1996-11-05 — — US disclosed
US-5514699-A Pharmaceutical compounds LILLY INDUSTRIES LIMITED (GB) 1996-05-07 — — US disclosed
EP-0618206-A1 Pharmaceutical compounds LILLY INDUSTRIES LIMITED (GB) 1994-10-05 — — EP disclosed
Send feedback